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dial infarction. A variety of treatment modalities have been used in patients with 
massive PE, which include systemic anticoagulation, catheter-directed thromboly-
sis (CDT) and etc. Methods: A Markov model was constructed to determine the 
costs and benefits of CDT with urokinase and CDT with alteplase. The time horizon 
of the model was lifetime, and a monthly cycle length was adopted. A review of 
the literature was undertaken to identify the primary studies used to populate 
the decision model. Direct medical costs were assessed from the payer perspec-
tive in the Kazakhstan and analyzed using sensitivity analyses. A Monte Carlo 
analysis with 1000 patients was performed to obtain mean. Results: Compared 
with heparin, CDT was associated with a significant reduction of overall mor-
tality. This reduction was not statistically significant after exclusion of studies 
including highrisk PE. However, major hemorrhage and fatal or intracranial bleed-
ing were significantly more frequent among patients receiving CDT. The multi-
way sensitivity analysis showed that CDT was cost-effective only under specific 
scenarios. The expected costs per patient were $1,656 for CDT with urokinase 
and $990 for CDT with alteplase (difference $666). The mean cost-effectiveness 
ratio was $235,950 per CDT with urokinase and $487,229 for CDT with alteplase. 
Probabilistic sensitivity analysis showed that CDT with urokinase was more effec-
tive and less costly (dominant) in 23% of all simulations. ConClusions: The 
analysis showed that CDT might be cost-effective in sub-groups of patients at 
high risk of death from PE. The use of CDT with urokinase for the treatment of 
haemodynamically stable patients with PE was more cost-effective than CDT with 
alteplase in the Kazakhstan. The fact that when using alteplase have a higher risk 
of hemorrhage than with urokinase is also preferences for the use of urokinase 
for CDT.
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objeCtives: The objective of this investigation was to assess the evidence base 
by performing a systematic review of randomized controlled trials of Mipomersen 
for treatment of hypercholesteremia. Methods: Studies published in English 
language were collated from PubMed and Cochrane databases using validated 
search strategies. Pre-specified inclusion/exclusion were employed to identify 
randomized controlled trials (RCTs), including Mipomersen based therapy. Two 
researchers independently screened the studies and extracted the data. Analysis 
of comparable outcomes was performed using random-effects model to calculate 
summary weighted mean difference (WMD) and 95% CI using statistical software 
R. Results: Nine studies were finally included for data extraction. Overall effect 
size (WMD(95%CI)) were -0.42 (-0.66,-0.18),-0.24 (-0.37,0.12), -44.18 (-52.74,-35.63), 
-55.80 (-77.36,-34.24) and 0.16(-0.01,0.33) for Apo B, VLDL, LDL, Non-HDL, and HDL 
respectively. Mipomersen was associated with a reduction in LDL-C concentrations 
from baseline at the primary efficacy time point. The mean percentage change 
from baseline in LDL-C concentration was significantly greater with Mipomersen 
than with placebo. For the secondary and tertiary outcome measures, percentage 
changes from baseline were significantly greater with Mipomersen than with 
placebo for apo B, total cholesterol, non-HDL-C. Mipomersen treatment also 
resulted in a significant percentage reduction when compared with the placebo 
group for lipoprotein (a) concentration and LDL-C: HDL-C ratio. The most common 
adverse events were injection-site reactions, influenza-like symptoms, patients 
in Mipomersen group, increase in intrahepatic triglyceride content, increased 
ALT concentrations. ConClusions: The findings show that evidence supports 
Mipomersen being safe and effective intervention as an adjunctive drug for low-
ering LDL-C.
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objeCtives: Since the optimal Venous Thromboembolism (VTE) prophylaxis strat-
egy for trauma patients is unknown, we performed this study to compare the effec-
tiveness of the use of pharmacological thromboprophylaxis such as Low Molecular 
Weight Heparin (LMWH) to the non-pharmacological thromboprophylaxis such as 
pneumatic compression devices (PCDs) in the prevention of Deep Vein Thrombosis 
(DVT) among major trauma patients. Methods: A simplified decision-analysis 
model was established. The outcome measures for this model were the expected 
utilities resulting for each of the comparison categories. Our model compares 
two strategies, LMMW and PCDs. Patients who received LMWH as prophylactic 
approach will then have the chance to either develop DVT or not develop DVT. As 
some patients develop DVT the have four different chances; to die from DVT, survive 
DVT survive DVT but suffer from bleeding complications, or survive DVT but suffer 
from Heparin Induced Thrombocytopenia (HIT). The expected utility then calculated 
based on the terminal node utility and probability of each possible event. On the 
second hand, PCDs patients will either develop DVT or not based on the probabili-
ties. If developed DVT, they might die, survive, suffer bleeding or suffer Local Tissue 
Injury (LTI). If no DVT, they still suffer the same complications but no death due to 
DVT. Results: The LMWH strategy has a bigger expected utility comparing to that 
for PCDs (0.9904 vs. 0.9865). The difference in the expected utility is about 0.0039 
makes the decision to choose the LMWH strategy that provides the highest possible 
utility. In a one-way sensitivity analysis on the probability of DVT with LMWH. PCDs 
are insensitive to this parameter. As the probability of DVT with LMWH below 0.0285 
then LMWH is the effective strategy. PCDs become the effective strategy when the 
probability of DVT with LMWH exceeds 0.0285. ConClusions: When compared 
the mechanical PCDs as thromboprophylaxis with the pharmacological LMWH, 
LMWH is more effective.
the only eHealth component were excluded. Two authors independently screened 
all studies. The quality of each study was also assessed. Results: eHealth is a rap-
idly growing intervention: 40%, 16%, and 5% of studies included were published in 
2014, 2013, and 2012, respectively. Of the included studies, a variety of diseases were 
represented, with most studies focusing on cardiac disease, depression, diabetes, 
and respiratory diseases. 25% of the studies targeted chronic disease in general. A 
majority of studies explored eHealth in monitoring and maintenance of chronic 
disease. Outcomes to assess program efficacy were often measured using changes 
in disease specific outcomes, while few studies provided economic outcomes. Long 
term outcomes were not commonly assessed but implied through surrogate out-
comes. ConClusions: Current evidence suggests that eHealth has the potential 
to help patients and medical professionals better control chronic disease related 
events and decrease rising healthcare costs. However, measurement of long term 
event avoidance and patient quality of life is needed to develop meaningful and 
effective programs and to allocate eHealth appropriately.
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objeCtives: The novel oral anti-coagulants (NOACs) have not been compared 
directly in a randomized controlled trial (RCT) examining the initial treatment of 
venous thromboembolism (VTE). A systematic review and network meta-analysis 
(NMA) were conducted to compare the efficacy and safety of the NOACs in this 
indication. Safety with respect to bleeding is a major concern for physicians and 
patients. Methods: Electronic databases were systematically searched (July 
2014) to identify randomized controlled trials (RCTs) evaluating apixaban, dabi-
gatran, rivaroxaban, and edoxaban versus standard care. Eligible adult patients 
had objectively confirmed deep vein thrombosis (DVT), pulmonary embolism 
(PE) or both. A fixed-effect Bayesian NMA was conducted for relevant out-
comes. Results: Six phase III RCTs were included: apixaban (AMPLIFY [n= 5,395]); 
rivaroxaban (EINSTEIN-DVT/PE pooled [n= 4,832+3449]); dabigatran (RE-COVER I/
II [n= 2,539/2568]); edoxaban (Hokusai-VTE [n= 8,292]). The relative risk of ‘VTE 
and VTE-related death’ was lower with apixaban compared with both dabigatran 
(↓24%, 0.76 [0.46, 1.26]), rivaroxaban (↓7%, 0.93 [0.59, 1.45]) and edoxaban (↓6%, 
0.94 [0.62, 1.42]). Apixaban was associated with the most favorable safety profile, 
showing a statistically significant reduction in the risk of ‘major or clinically rel-
evant non-major (CRNM) bleed’ compared with rivaroxaban (↓53%, 0.47 [0.36, 0.61]), 
dabigatran (↓31%, 0.69 [0.51, 0.94]) and edoxaban (↓46%, 0.69 [0.51, 0.94]). The rela-
tive risks of all-cause mortality for apixaban versus dabigatran, rivaroxaban and 
edoxaban were comparable (21%, 0.79 [0.44, 1.40]; 18%, 0.82 [0.50, 1.34]; 25%, 0.75 
[0.47, 1.21], respectively). ConClusions: While the NOACs have similar efficacy 
in terms of reduction in VTE or VTE-related death, apixaban had a significantly 
better safety profile versus other NOACs in terms of reduction in ‘major or CRNM 
bleed’ for initial/long term treatment of VTE.
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objeCtives: The complexity of therapy and pill burden has a direct impact on 
treatment compliance. Compliance is improved when agents are prescribed as 
fixed dose combinations rather than separate pills. This could be of particular 
value in elderly patients with multiple morbidities requiring polypharmacy. This 
systematic review aims to at evaluating efficacy and safety of the once-daily fixed-
dose-combination (bisoprolol+amlodipine) on SAH. Methods: Electronic searches 
included MEDLINE, LILACS, EMBASE, CRD, among others until June 2014. Search 
terms included “Amlodipine”, “Bisoprolol” and “Hypertension” via MESH controlled 
vocabulary. Where included studies with information on patients using the combi-
nation for hypertension treatment. Two reviewers performed the search. Results: 
From 704 articles found, 3 evaluated efficacy. Mean reduction of 19.7% in DBP, from 
103.9±9.6 mmHg at baseline to 83.4±6.2 mmHg (p< 0.0001). SBP decreased from 
20.4% to 21,8% and DBP decreased19.7% to 21.2%. SBP/DBP goal (< 140/90 mmHg) 
was reached or exceeded from 82.5 to 89.0% of patients by the end of 8 weeks. HR 
presented reductions from 10.4% to 21.65% to the end of 8 weeks (from 87.3 ± 11.07 
bpm to 68.4 ± 8.13 bpm). Pedal edema was observed in 7.5% to 8%. Excellent/good 
tolerability was reported by 90.6% to 94% of patients. Combination therapy is likely 
to cause fewer AEs with lower doses. Benefits of fixed-dose include reduced pill 
burden, improved BP control, compliance and cost savings. Persistence rate of 58.3% 
compared to 14.9% and a compliance rate of 76.9% versus 54.4% were observed. 
Patients with HR > 79 bpm had an 89% greater risk of mortality than those with HR 
≤ 79 bpm. ConClusions: In summary, bisoprolol plus amlodipine in a fixed-dose 
combination showed to improve response rate, with a similar safety profile when 
compared with amlodipine and bisoprolol in monotherapy, potentially leading to 
an increase in SAH treatment compliance.
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objeCtives: Massive pulmonary embolism (PE) is a life-threatening condition 
associated with a high incidence of fatalities comparable to that of acute myocar-
